FDA approves maraviroc tablets.
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D017277:Drug Approval; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D000077592:Maraviroc; D013607:Tablets; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D013607:Tablets; D014230:Triazoles; D000077592:Maraviroc